For those with ALK+ NSCLC who received first-line, next-generation ALK TKI monotherapy, continuing ALK TKI with chemotherapy is linked to better outcomes.

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

Half of patients diagnosed with advanced non-small cell lung cancer were alive 6.8 years after diagnosis, according to new study findings. Half of patients diagnosed with stage 4, ALK-positive ...

Antagonists of growth hormone-releasing hormone potentiate radiation response in prostate cancer. Background: A small subset of human lung cancer harbors the fusion of the gene for echinoderm ...

About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until ...